Search PubMed⌕ Search

Biomedical subjects

Z Boda

Publications and source records attributed to Z Boda.

At least 55 records · Page 3Linked to original sources
PubMed1990

The use of polybrene for heparin neutralization in protein C activity assay.

The protein C activity assay of Francis and Patch (Thromb Res 1983; 32: 605-613) is based on the prolongation of the activated partial thromboplastin time in the presence of activated protein C isolated from the test samples. The assay was modified and standardized by Rapaport et al. (Am J Clin Pathol 1987; 87: 491-497), but could still only be used in patients on heparin therapy after chromatographic removal of the heparin. In this study we attempted to eliminate the heparin separation step without losing the advantages of the modified (Rapaport) method. Heparin was added to the isolated protein C to obtain a rapid and complete antithrombin effect after the thrombin activation step and polybrene was subsequently used to neutralize the excess heparin. Using this modified assay protein C activity ranged from 67 to 133% in the normal population, and from 9 to 25% in coumarin-treated patients. Precision of the modified method was acceptable in both normal and pathological PC ranges: within- and between-batch variations were 5.6 and 3.6%, and 8 and 14%, respectively. The assay correlated well (r = 0.84) with the ELISA technique in both healthy donors and non-coumarin-treated patients.

Biological Assay↗
PubMed1989

[Subcutaneous heparin-calcium therapy: clinical and laboratory experience].

Fifty patients with acute deep vein thrombosis, pulmonary embolism, acute myocardial infarct and priapism were treated with subcutaneous calcium heparin. Laboratory control was based on the examination of APTT. On the first day of heparin therapy only 52% of patients's APTT was 1.5 times greater than control value but the ratio increased to 82% on the fifth day of treatment. The importance of initial venous sodium heparin bolus (5-10,000 U) followed immediately by subcutaneous calcium heparin is emphasized. Injection of 500 U/kg/day calcium heparin divided in two equal doses is recommended. Four thrombotic and two haemorrhagic complications were observed. Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.

Calcium↗
PubMed1989

[Successful delivery of a patient with two artificial valves (mitral and aortic)].

The authors report the case of the successful delivery of a 35-year old woman who underwent a double Sorin tilting disc valve replacement because of severe mitral and aortic valve disease in NYHA III-IV. functional class six years ago. Beside reporting on outcome of the case and complications, they mention the possible other complications too, endangering the life prospects of the mother and child that can come about as a result of the diminished pump function of the myocardium, blood coagulation changed during pregnancy and due to the hemmorrhagic and teratogenic consequences of anticoagulant treatment.

Adult↗
PubMed1989

[Thrombotic microangiography (thrombotic thrombocytopenic purpura and hemolytic uremia syndrome)].

Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome have quite uniform or identical histopathological features and share very similar clinical characteristics, so thrombotic microangiopathy may be used as a common descriptive term of the two syndromes. During the past one and a half year five patients with thrombotic microangiopathy, receiving plasma therapy were observed by the authors. Owing to the early, correct diagnosis and plasma administration four patients had been recovered from the disease. The evaluation of clinical signs and symptoms, altogether with some simple laboratory data (megakaryocytic thrombocytopenia, nonimmune acquired haemolytic anaemia, renal insufficiency, neurologic alterations, etc.) remained essential in the recognition and treatment of thrombotic microangiopathy. After giving a short review of the literature the authors deal with the results of some more specific examinations (prostanoids, beta-thromboglobulin, the quantitative and qualitative analysis of Willebrand factor, etc.) which may give further data to the complex aetiopathogenesis of thrombotic microangiopathy.

Adolescent↗
PubMed1989

Congenital factor XIII deficiency with multiple benign breast tumours and successful pregnancy with substitutive therapy. A case report.

A 34-year-old woman with congenital factor XIII (FXIII) deficiency and multiple connective tissue tumours is reported. The subunit a of FXIII was totally absent in her plasma, platelets and histiocytes of breast fibroadenomas and considerably reduced in the monocytes (below 5%). The plasmatic level of subunit b was also reduced (25%). She had a bleeding tendency and habitual abortions. Fresh frozen plasma therapy permitted a successful pregnancy.

Adult↗
PubMed1988

Monocytes of patients congenitally deficient in plasma factor XIII lack factor XIII subunit a antigen and transglutaminase activity.

Monocytes isolated from patients with severe deficiency in plasma Factor XIII of blood coagulation (FXIII) were tested for FXIII antigen and transglutaminase activity. By immunoperoxidase method the patients' monocytes, in contrast to normal controls, showed no reaction with a monospecific antibody against FXIII subunit a. This result was confirmed by immunoblotting technique, as well. In addition, tissue macrophages tested in one of the patients were also exempt of FXIII subunit a antigen. The transglutaminase activity in FXIII deficient monocytes was below the limit of the detection of the dansylcadaverine incorporation assay. The results suggest that FXIII subunit a of monocytes/macrophages and its plasma and platelet counterparts are closely related or identical proteins and demonstrate that the transglutaminase activity in monocytes is of FXIII origin and tissue transglutaminase is present, if at all, only in insignificant amount.

Antigens↗
PubMed1986

Platelet function studies in myeloproliferative disorders.

Platelet functions were studied in 64 patients with various myeloproliferative diseases. The characteristic alterations were prolonged bleeding time, decreased platelet aggregation (but normal results induced by ristomycin), elevated level of BTG, high production of MDA, increased level of TXB2 with almost normal level of 6-keto-PGF1. However, considering the bleeding time and the amount of BTG in relation to the whole blood platelet count, no differences could be detected.

6-Ketoprostaglandin F1 alpha↗
PubMed1985

Aggristin (ristomycin) precipitation test: a new tool for the detection of fibrin monomer and fibrin degradation products.

The specific detection of fibrin monomer and fibrin degradation products is of high importance in the laboratory diagnosis of intravascular clotting (disseminated intravascular coagulation, deep vein thrombosis). The methods proposed until now are partly time-consuming, needing special laboratories or insensitive and poorly specific. Applying ristomycin instead of ristocetin (another member of the vancomycin antibiotics) a new simple, specific and sensitive method has been elaborated and recommended for the laboratory diagnosis of intravascular coagulation and its differentiation from primary fibrinogenolysis. The results obtained from in vitro and animal experiments and from human studies are presented.

Animals↗